亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

3S3-[4-[(2-氯-5-碘苯基)甲基]苯氧基]四氫呋喃

 
 
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 惠誠
過期 長期有效
更新 2017-07-19 09:59
 

濟南惠誠醫藥科技有限公司

企業會員第10年
資料未認證
保證金未繳納
詳細說明

中文名稱: (3S)-3-[4-[(2--5-碘苯基)甲基]苯氧基]四氫呋喃

中文同義詞: (3S)-3-[4-[(2--5-碘苯基)甲基]苯氧基]四氫呋喃;(S)-3-(4-(5--2-氯芐基)苯氧基)四氫呋喃;(3S)-3-[4-[(2--5-碘苯基)甲基]苯氧基]四氫呋喃(依帕列凈中間體);依帕列凈雜質 C;(S)-3-(4-(2--5-碘芐基)-苯氧基)-四氫呋喃;(S)-3-(4-(2--5-碘苯)苯氧基)四氫呋喃

英文名稱: (3S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-furan

英文同義詞: (3S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-furan;(S)-3-(4-(2-chloro-5-iodobenzyl)phenoxy)-tetrahydrofuran;(S)-3-(4-(2-chloro-5-fluorobenzyl)phenoxy)-tetrahydrofuran;EMpagliflozin iMpurity C;(S)-4-iodo-1-chloro-2-(4-tetrahydrofuran-3-yloxy-benzyl)-benzene;(3S)-3-{4-[(2-chloro-5-iodophenyl)methyl]phenoxy}oxolane;(3S)-3-[4-(2-chloro-5-iodobenzyl)-phenoxy]-tetrahydrofuran;Furan, 3-[4-[(2-chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-, (3S)-

CAS: 915095-94-2

分子式: C17H16ClFO2

分子量: 306.7591432

用途:依帕列凈中間體;艾帕列凈中間體;艾拉列凈中間體;伊帕列凈中間體;恩格列凈中間體

舉報收藏 0評論 0
更多>本企業其它產品
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |